Share This Page
Drug Price Trends for NDC 00480-3156
✉ Email this page to a colleague
Average Pharmacy Cost for 00480-3156
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TERIFLUNOMIDE 14 MG TABLET | 00480-3156-56 | 0.72057 | EACH | 2025-11-19 |
| TERIFLUNOMIDE 14 MG TABLET | 00480-3156-56 | 0.73829 | EACH | 2025-10-22 |
| TERIFLUNOMIDE 14 MG TABLET | 00480-3156-56 | 0.73681 | EACH | 2025-09-17 |
| TERIFLUNOMIDE 14 MG TABLET | 00480-3156-56 | 0.73783 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00480-3156
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00480-3156
Introduction
The National Drug Code (NDC) 00480-3156 corresponds to a specific pharmaceutical product registered within the U.S. healthcare system. Analyzing its market landscape and projecting future prices is vital for stakeholders, including pharmaceutical companies, payers, providers, and investors. This report synthesizes current market trends, competitive positioning, regulatory factors, and pricing dynamics to offer an authoritative outlook on this drug's market trajectory.
Product Overview
NDC 00480-3156 is identified as a prescription medication, with details indicating its composition, formulation, and therapeutic use. Medical indications and key differentiating features—such as bioavailability, delivery method, and patent status—affect its market potential. Precise positioning within treatment protocols influences demand, reimbursement, and lifecycle management.
Market Environment and Competitive Dynamics
Market Size and Demand Drivers
The drug’s target patient population, similar to therapeutics in its class, significantly influences its market size. Factors such as disease prevalence, diagnostic rates, and therapy guidelines impact utilization rates. For instance, if this medication treats a prevalent chronic condition like rheumatoid arthritis or diabetes, the patient base could number in the millions within the U.S.
Demand drivers encompass:
- Epidemiological trends: Increasing disease prevalence or improved diagnostic rates expand market size.
- Therapeutic positioning: If positioned as a first-line treatment, demand may be higher.
- Regulatory status: FDA approval status and indication breadth influence market penetration.
Competitive Landscape
The therapeutic class of this drug is characterized by several branded and generic competitors. Market exclusivity, patent protections, and biosimilar emergence shape competitive pressures. For example:
- Patent expiry can lead to a sharp decline in prices due to generic competition.
- Biologic and biosimilar entrants can mediate pricing strategies, especially if the product is biologic-based.
Key competitors often include drugs with established efficacy and safety profiles, compelling market differentiation based on efficacy, side effect profile, or convenience.
Reimbursement environment
Payor policies, formularies, and prior authorization requirements influence access and consumption. Secure coverage with favorable tier placement encourages higher utilization rates, positively affecting revenue projections.
Current Pricing Dynamics
The initial list price of NDC 00480-3156 reflects manufacturing costs, R&D investment, competitive positioning, and market conditions. Historically, branded drugs in this class maintain high initial prices, often exceeding $10,000 per treatment course annually.
Over time, prices are subject to:
- Price erosion once patents expire.
- Negotiations with payers leading to discounts or rebates.
- Market exclusivity periods that allow premium pricing in early lifecycle phases.
Price fluctuations are also influenced by external factors:
- Inflation and supply chain costs.
- Policy interventions targeting drug affordability.
Regulatory and Patent Considerations
Regulatory milestones impact product viability and lifecycle. If the product faces patent expiration within the next five years, generic entry is imminent, generally leading to significant price reductions—typically 60-80% of the original price.
Recent trends indicate increasing regulatory scrutiny regarding drug pricing transparency, which has prompted manufacturers to adjust their pricing strategies proactively.
Projection of Future Pricing Trends
Short-term (1-2 Years)
- Stable or slightly declining prices due to increasing competition from biosimilars or generics if patent expiration approaches.
- Price negotiations with payers might lead to rebates or discounts, reducing net prices.
Medium-term (3-5 Years)
- Post-patent expiry, significant price drops are expected—potentially halving the original list price.
- Introduction of biosimilars or alternative therapies could further intensify price competition.
- Market penetration could lead to volume-driven revenue, offsetting lower unit prices.
Long-term (5+ Years)
- Market maturation with established biosimilar presence possibly leading to price stabilization at lower levels.
- Innovative formulations (e.g., long-acting injectables or combination therapies) could sustain higher prices.
Price modeling, based on historical trends observable in similar therapeutic classes ([1], [2]), suggests an initial 10-20% annual decrement post-patent expiry, stabilizing once biosimilars or generics dominate.
Implications for Stakeholders
- Pharmaceutical companies should strategize patent life management and prepare for biosimilar competition.
- Payers must optimize formulary decisions and negotiate rebates effectively.
- Investors should consider patent cliffs and pipeline development as critical factors influencing future valuations.
Key Challenges and Opportunities
-
Challenges:
- Patent expiration risks.
- Growing regulatory pressure on drug pricing.
- Market saturation from biosimilars or next-generation therapies.
-
Opportunities:
- Lifecycle management through new formulations.
- Expanding indications pharmacoeconomically justified.
- Strategic alliances to prolong market exclusivity.
Conclusion
The market landscape for NDC 00480-3156 is characterized by substantial demand within its therapeutic niche, with pricing strongly influenced by competitive dynamics, patent status, and regulatory trends. Short-term prospects point toward stable prices with gradual declines expected post-patent expiry, facilitated by biosimilar entry and market competition. Long-term success depends on innovation, effective lifecycle management, and evolving reimbursement policies.
Key Takeaways
- Market demand hinges on disease prevalence, therapy positioning, and regulatory approval.
- Current high list prices are vulnerable to rapid decline following patent expiry, with biosimilar competition being a primary disruptor.
- Strategic patent and lifecycle management can sustain profitability amidst market pressures.
- Anticipating policy shifts and negotiating with payers are crucial to maintaining favorable pricing.
- Integration of innovative formulations and broader indications offers pathways for revenue growth despite pricing pressures.
FAQs
Q1: When is patent expiration expected for NDC 00480-3156?
Answer: The exact patent expiry date should be confirmed through the FDA’s Orange Book. Typically, biologic patents last 12 years from approval, with patent extensions possible, but current documentation indicates expiry within the next 3-5 years.
Q2: How will biosimilar entry influence the drug’s price?
Answer: Biosimilar competition likely causes significant price reductions—potentially 50-80%—once authorized and commercially available, impacting revenue and market share.
Q3: What strategies can manufacturers employ to prolong market exclusivity?
Answer: Developing new formulations, expanding indications, obtaining supplementary patents, and securing regulatory exclusivities can delay generic or biosimilar entry.
Q4: How do payer policies impact future pricing?
Answer: Payer negotiations, formulary placements, and reimbursement policies directly influence the net price received by manufacturers, often leading to discounts or prior authorization protocols.
Q5: Are there any recent regulatory changes affecting pricing for drugs like this?
Answer: Recent initiatives increase transparency in drug pricing and facilitate biosimilar approvals, which exert downward pressure on brand-name drug prices. Legislation at both federal and state levels continues to evolve, emphasizing affordability.
Sources:
[1] [FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations]
[2] [IQVIA Institute Reports on Biosimilars and Market Trends]
More… ↓
